| Course | NR 668 Psychiatric-Mental Health Capstone Practicum & Intensive |
|---|---|
| Week | 7 |
| Paper type | Practice question brief |
| Length | About 1,100 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | October 2026 |
Free sample paper for NR 668 Week 7
Practice Question Brief: Should an Antidepressant Ever Be Part of Treatment for Bipolar II Depression, and Where I Land
Student Name
College of Nursing, Chamberlain University
NR 668: Psychiatric-Mental Health Capstone Practicum & Intensive
Instructor Name
Month Day, Year
Practice Question Brief: Should an Antidepressant Ever Be Part of Treatment for Bipolar II Depression, and Where I Land
The Question, Left Open
Should an antidepressant ever be part of treatment for bipolar II depression, and if so, when? This is not a question with a known answer that only needs looking up. Guidelines, task forces and experienced clinicians disagree, and the disagreement is about real trade-offs.
Why It Is Unsettled
Bipolar II disorder is dominated by depression, and many patients spend far more time depressed than hypomanic. The medications with the best evidence for bipolar depression carry metabolic or tolerability costs. Antidepressants are familiar and often well tolerated. Against that, they carry a risk of switching into hypomania or mixed states and, possibly, of faster cycling. Most trials of antidepressants in bipolar disorder enrolled mainly bipolar I patients, so what is known about switching may not apply evenly to bipolar II. The evidence is thin where the question is sharpest.
Position 1: Avoid Antidepressants
The strongest case: in a large randomized trial, adding an antidepressant to a mood stabilizer did not improve recovery from bipolar depression compared with placebo (Sachs et al., 2007). If they do not help, any switching risk is a cost without a benefit. The international task force advised against antidepressant monotherapy in bipolar I disorder and against antidepressants in patients with mixed features (Pacchiarotti et al., 2013). Supporters: many specialist clinicians, especially for patients with mixed features or rapid cycling.
Position 2: Cautious Use, Selected Patients
The strongest case: bipolar II disorder may carry a lower switch risk than bipolar I, and the current Canadian and international guideline lists sertraline and venlafaxine among second-line options for bipolar II depression (Yatham et al., 2018). Some patients have a clear history of response to an antidepressant without switching, and denying them a treatment that worked seems hard to justify. The task force also allowed that adjunctive antidepressants may be considered for patients with a history of positive response, without mixed features (Pacchiarotti et al., 2013). Supporters: guideline authors for bipolar II specifically, and clinicians in primary care settings.
Position 3: Use Freely, as in Unipolar Depression
The strongest case: some clinicians argue that the line between bipolar II and recurrent unipolar depression is blurred, and that withholding antidepressants leaves patients depressed for longer. Supporters exist, mostly among clinicians who see patients with mild or uncertain bipolarity, but the evidence for this position is the weakest of the three, and neither the guideline nor the task force supports it.
Where the Evidence Is Thin
On bipolar II specifically, on long-term switch rates with modern antidepressants and on which patients are safe to treat. Weak studies cannot settle these, and the brief does not pretend they do.
Where I Land
Between positions 1 and 2. I would not use an antidepressant as monotherapy in bipolar II disorder. I would not use one in a patient with current or recent mixed features, which rules it out for the patient in my capstone case. I would consider an antidepressant only as an addition to a mood stabilizer or antipsychotic, in a patient without mixed features, with a documented history of response without switching, and with the patient and family taught to report early signs of hypomania. I would stop it if any mixed or hypomanic symptoms appeared.
The Cost of Being Wrong
If I am too cautious, some patients will stay depressed longer or carry metabolic burdens from alternatives when an antidepressant might have helped. If I am too permissive, some patients will switch into hypomania or a mixed state, which in bipolar disorder can raise suicide risk and damage work and relationships. For the patient in my capstone case, mixed features made the cost of permissiveness higher, which is why the antidepressant was stopped.
How This Applies to Patients I Will See
In primary care and outpatient psychiatry, the most common version of this question arrives as a patient already on an antidepressant who turns out to have bipolar II disorder. For that patient, my position means stopping the antidepressant if there are mixed features, as with my capstone patient, and considering a slow taper with close monitoring if there are not. It also means asking about hypomania before starting any antidepressant in a patient with a family history of bipolar disorder, since screening and collateral can find bipolarity the patient does not report (Hirschfeld et al., 2000).
What Patients Should Hear
That the question is debated among experts, that the plan reflects the evidence available, and what signs of hypomania or a mixed state they and their family should watch for. Patients can tolerate uncertainty better than a confident answer that later changes. My capstone patient, told that experts disagree about antidepressants in bipolar disorder, said it made the decision to stop escitalopram easier to accept, because it was explained rather than announced.
How the Position Was Formed
The position came from reading the trial, the task force and the guideline side by side, and from the capstone patient, whose mixed features made the choice easy. A patient without mixed features and with a clear history of antidepressant response would test the position harder, and I have not yet treated one. The position is therefore provisional in a specific way: it is firmest where my own experience is, and least tested where the evidence is thinnest. I will revisit it after treating patients who test it, and record what changes. A position that never changes after meeting new patients is a habit rather than a judgment, and the brief is written to be revised.
Who I Would Consult
For a patient with bipolar II depression who has not responded to two first-line options and has a clear past response to an antidepressant, without any history of switching, I would discuss the case with a psychiatrist before adding one, because the decision sits at the edge of the evidence.
What Would Change My Mind
A well-designed trial in bipolar II disorder showing benefit from adjunctive antidepressants without increased switching, or a clear subgroup with low switch risk identified in advance. Until then, the burden of proof sits with adding the antidepressant, not with leaving it out. That is where I stand at the end of this term, and it is a position I expect to defend to patients, colleagues and myself.
References
Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Jr., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., Russell, J. M., Sachs, G. S., & Zajecka, J. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. American Journal of Psychiatry, 157(11), 1873-1875. https://doi.org/10.1176/appi.ajp.157.11.1873
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., Tondo, L., Findling, R. L., Youngstrom, E. A., Tohen, M., Undurraga, J., González-Pinto, A., Goldberg, J. F., Yildiz, A., Altshuler, L. L., . . . Vieta, E. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170(11), 1249-1262. https://doi.org/10.1176/appi.ajp.2013.13020185
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., Ketter, T. A., Patel, J., Hauser, P., Rapport, D., Martinez, J. M., Allen, M. H., Miklowitz, D. J., Otto, M. W., Dennehy, E. B., & Thase, M. E. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356(17), 1711-1722. https://doi.org/10.1056/NEJMoa064135
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O'Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., . . . Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609
Reading the NR 668 Week 7 instructions
State the question in a form that admits it is contested; most drafts phrase it as if an answer exists and only needs looking up. Explain why it is unsettled, including where the evidence is thin. Give two or three defensible positions their strongest case and their real supporters in the literature, so the disagreement is visibly genuine. Where the evidence is weak, say so instead of citing weak studies as though they settled things. Then take a position yourself, with the conditions under which it applies. Name the cost of being wrong in each direction. Say how the position applies to patients you will actually see, and what would change your mind.
How this NR 668 Week 7 example is built
The sample asks whether antidepressants belong in bipolar II depression. It explains that most trials enrolled bipolar I patients, so switch risk in bipolar II is uncertain. Avoidance is supported by a large trial showing no added benefit and a task force advising against use in mixed states. Cautious use is supported by a guideline listing sertraline and venlafaxine as second-line for bipolar II and by task force allowance for prior responders without mixed features. Free use has the weakest support. The writer lands between the first two, rules out monotherapy and mixed states, names the costs of over- and under-caution and explains what patients should hear. A closing section says the burden of proof sits with adding the antidepressant.
Reading the NR 668 Week 7 grading rubric
Practice question briefs lose most when the question is phrased as settled, turning the brief into a literature summary. Next is a straw opposing position, which makes the writer's own position look stronger than it is. Many briefs cite weak studies as if they settled the question rather than saying the evidence is thin. Writers often refuse to take a position at all, which leaves the reader with a survey. Positions stated without conditions are hard to apply to a real patient. Briefs that never name the cost of being wrong treat the question as academic, though each error falls on a patient. A missing statement of what would change the writer's mind makes the position look fixed.
Common NR 668 Week 7 mistakes, and how to avoid them
Writing honestly about a question without a settled answer means resisting the urge to pick the most-cited answer and stop. Starting from your draft, we can help you frame the question as open, give each position its strongest case and say where the evidence is thin. We can also help you take a position with conditions and name the cost of being wrong. Testing the position against a patient you have treated is often what sharpens its conditions. The question and your position are yours. We can also help you apply the position to the next patient you are likely to see.
Get a NR 668 Week 7 example written to your instructions
Send the Week 7 instructions with the question your section set, since the whole brief is shaped by it, and a custom example is written to that question and returned inside 24 to 48 hours. The first one is free. Any word limit or citation count helps as well.
More NR 668 papers and PMHNP samples
- NR 668 Week 1: Case Selection Post
- NR 668 Week 2: Case Conference Write-Up
- NR 668 Week 3: Evaluation Note
- NR 668 Week 4: Case Defense
- NR 668 Week 5: Panel Review
- NR 668 Week 6: Safety Decision Write-Up
- NR 668 Week 8: Capstone Case Paper
- NR 546 Week 7: Medication Education Handout
- NR 607 Week 7: Hematology Consultation Write-Up
- NR 547 Week 7: Medical Mimic Brief
- NR 606 Week 7: Progress Note Series
NR 668 Week 7 questions, answered
Am I allowed to disagree with published guidance?
Usually yes, provided the disagreement is argued rather than asserted. Guidance is written for populations and a brief is often about a patient the guidance fits badly, which is a legitimate case to make. What sections do not reward is dismissing guidance without engaging with the evidence behind it, or citing it as though quoting a document ends an argument the assignment set up as open.
How many sources does a brief like this take?
Fewer than a paper of the same length, and your section will usually state a minimum. The measure that matters is whether each source is doing work: establishing that a position has support, showing where two findings conflict, or fixing a number the argument depends on. Six sources placed against specific claims read stronger than fifteen listed at the end.
Can I write the brief in the first person?
Most sections allow it in the closing position and prefer neutral construction in the review of the competing views, but check the instructions. Where first person is permitted, it usually improves the document, because the assignment is asking what this writer would do and a passive construction hides exactly the thing being assessed.
Where can I find a free NR 668 Week 7 sample paper?
The finished practice question brief on antidepressants in bipolar II depression is available here in full.
Where does the NR 668 Week 7 brief land on antidepressants in bipolar II?
Never as monotherapy or with mixed features, and only as an addition to a mood stabilizer in a past responder without switching, with close monitoring.